Pharmaceutical Manufacturing Handbook: Production and

56 REGULATORY CONSIDERATIONS IN APPROVAL
REFERENCES
1. Congressional Budget Offi ce ( 1998 ), How Increased Competition from Generic Drugs
Has affected Prices and Returns in the Pharmaceutical Industry , Congressional Budge
Offi ce , Washington, DC .
2. Crawford , L. M. , Acting Commissioner of the Food and Drug Administration, in a Speech
to the Generic Pharmaceutical Association on February 26, 2005, available: http://www.
fda.gov/oc/speeches/2005/GPhA0301.html , accessed Apr. 23, 2005.
3. Comments of the Generic Pharmaceutical Association (GPhA) (Sept. 29, 2006), available:
http://www.gphaonline.org/AM/Template.cfm?Section=Media&Template=/CM/
HTMLDisplay.cfm&ContentID=2849 , accessed Jan. 23, 2007.
4. Schellekens , H. ( 2005 ), Follow - on biologics: Challenges of the “ next generation ” ,
Nephrol. Dial. Transplant . 20 ( Suppl. 4 ), iv31 – iv36 .
5. Congressional letter from Senators O. Hatch and H. Waxman to Andrew von Eschenbach,
Acting Commissioner of the Food and Drug Administration (Feb. 10, 2006), available:
http://www.henrywaxman.house.gov/news_letters_2006.htm , accessed Dec. 21, 2006.
6. Messplay , G. C. , and Heisey , C. ( 2006 ), Follow - on biologics: The evolving regulatory landscape
, Bioexec Int. , May, 42 – 45 .
7. Biotechnol. Law Rept. , 2003 , 22(5), 485 – 508 .
8. Comments from R. Williams, U.S. Pharmacopoeia (USP), to FDA Docket No. 2004N -
0355, Mar. 15, 2005 .
9. Herrera , S. ( 2004 ), Biogenerics standoff , Nat. Biotechnol. , 22 ( 11 ), 1343 – 1346 .
10. Scott , S. R. ( 2004 ) What is a biologic ?, Chapter 1 in Mathieu , M. , Ed., Biologics Development:
A Regulatory Overview , 3rd ed., Paraxel Intl. , Waltham, MA , pp. 1 – 16 .
11. Federal Food Drug and Cosmetic Act , available: http://www.fda.gov/opacom/laws/fdcact/
fdctoc.htm , accessed Apr. 21, 2005.
12. Public Health Service Act , available: http://www.fda.gov/opacom/laws/phsvcact/phsvcact.
htm , accessed Apr. 21, 2005.
13. U.S. Department of Health and Human Services, Food and Drug Administration Transfer
of Therapeutic Products to the Center for Drug Evaluation and Research , available:
http://www.fda.gov/cber/transfer/transfer.htm , accessed Apr. 23, 2005.
14. U.S. Department of Health and Human Services (DHHS) ( 1999 , Oct.), Food and Drug
Administration, Center for Drug Evaluation and Research , Guidance for Industry:
Applications covered by Section 505(b)(2), DHHS, Washington, DC.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Omnitrope
(somatropin [rDNA origin]) questions and answers, available: http://www.fda.gov/
cder/drug/infopage/somatropin/qa.htm , accessed Dec. 21, 2006.
16. Letter of J. Woodcock. (CDER, FDA) to Docket Nos. 2001P - 0323/CP1, 2002P - 0447/CP1,
and 2003P - 0408/CP1 (Oct. 14, 2003 ).
17. Glidden , S. ( 2001 ), The generic industry going biologic , Biotechnol. Law Rept , 20 ( 2 ),
172 – 181 .
18. Letter from S. Galson (CDER, FDA) in response to Docket Nos. 2004P - 023 11CP1 and
SUP 1,2003P - 0 1 76lCP 1 and EMC 1, 2004P - 0171lCP1 and 2004N - 0355 (May 30, 2006 ).
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center
for Drug Evaluation and Research, Offi ce of Pharmaceutical Science, Offi ce of Generic
Drugs , Electronic orange book: Approved drug products with therapeutic equivalence
evaluations, available: http://www.fda.gov/cder/ob/default.htm , accessed Apr. 21, 2005.
20. Schellekens , H. ( 2004 ), How similar do “ biosimilars ” need to be ? Nat. Biotechnol . 22 ( 11 ),
1357 – 1359 .